drugset / Trial / NCT07577518

Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome

NCT07577518

RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of the incidence of major cardiovascular events between the combination of percutaneous intervention and optimal drug therapy and the optimal drug therapy alone in patients with chronic coronary syndrome. * Main RCT (Randomized Clinical Trial): Patients with chronic coronary syndrome enrolled in the study will be randomized in a 1:1 ratio to either 1) PCI(Percutaneous Coronary Intervention) plus optimal medical therapy or 2) optimal medical therapy alone, with clinical outcomes assessed during follow-up. (2,301 participants) * Nested RCT: An embedded randomized supplementary study was conducted on a subset (220 participants) of the total subjects. In patients who have decided to use beta-blockers for the control of angina, additional 1:1 randomization evaluates the efficacy of carvedilol sustained-release (SR) and immediate-release (IR) formulations. Both formulations are targeted for use up to the maximal tolerated dose, taking into account patient symptoms.

Timeline

Start
2026-06-15
Primary completion
2030-04-27
Completion
2034-03-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 3.125 mg
Subject Carvedilol Other / unclassified 6.25 mg
Subject Carvedilol Other / unclassified 8 mg
Subject Carvedilol Other / unclassified 12.5 mg
Subject Carvedilol Other / unclassified 16 mg
Subject Carvedilol Other / unclassified 25 mg
Subject Carvedilol Other / unclassified 32 mg
Subject Carvedilol Other / unclassified 50 mg
Subject Carvedilol Other / unclassified 64 mg
Subject Carvedilol Other / unclassified 128 mg